Financial Performance - Operating revenue for Q3 2024 was RMB 2,799,249,537.14, down 5.59% year-over-year, while year-to-date revenue was RMB 9,081,603,788.36, a decrease of 5.94%[2] - Net profit attributable to shareholders for Q3 2024 was RMB 501,763,106.12, an increase of 7.45% year-over-year, with year-to-date net profit at RMB 1,672,733,989.63, up 4.44%[2] - Basic earnings per share for Q3 2024 was RMB 0.54, reflecting an increase of 8.00% compared to the same period last year[2] - The company's operating revenue for the first nine months of 2024 was RMB 9,081.60 million, a decrease of 5.94% compared to RMB 9,654.79 million in the same period of 2023[6] - Operating profit increased to RMB 2,315,421,100.65, up 16.48% from RMB 1,987,239,809.53 year-on-year[17] - Net profit attributable to shareholders of the parent company reached RMB 1,672,733,989.63, representing a growth of 4.44% compared to RMB 1,601,554,878.96 in the previous year[17] - Total comprehensive income for the first nine months of 2024 was RMB 1,896,000,641.95, an increase from RMB 1,548,036,443.08 year-on-year[18] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 24,909,308,152.30, a decrease of 0.54% compared to the previous year-end[2] - The total current assets decreased from RMB 17,266,174,718.28 at the beginning of the year to RMB 16,613,394,001.59 at the end of the period[15] - The company's cash and cash equivalents decreased from RMB 11,325,723,855.76 to RMB 10,732,685,456.90[15] - The total non-current assets increased from RMB 7,778,652,409.47 to RMB 8,295,914,150.71[15] - Total liabilities decreased to RMB 9,973,518,408.08 from RMB 10,278,124,131.71, a reduction of 2.97%[16] - Current liabilities increased to RMB 9,013,265,318.62, up 11.43% from RMB 8,087,137,474.74 at the beginning of the year[16] - The company's total equity attributable to shareholders of the parent company rose to RMB 14,158,595,462.73, an increase from RMB 14,042,495,302.72[16] Cash Flow - The net cash flow from operating activities for the year-to-date period was RMB 2,307,915,362.28, reflecting a growth of 4.32%[2] - Operating cash inflow for the period (January to September 2024) was RMB 10,217,108,238.70, a decrease of 5.2% from RMB 10,775,261,897.57 in the same period of 2023[19] - Net cash flow from operating activities increased to RMB 2,307,915,362.28, up 4.3% from RMB 2,212,403,355.39 year-on-year[19] - Cash inflow from financing activities increased to RMB 3,166,957,767.39, up 14.3% from RMB 2,770,410,168.70 in the previous year[20] - Net cash flow from financing activities was negative at RMB -1,912,251,596.10, worsening from RMB -1,768,301,850.08 year-on-year[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,320, with the top ten shareholders holding significant stakes[8] - The largest shareholder, Hong Kong Central Clearing Limited, held 33.11% of the shares, amounting to 306,768,789 shares[8] - As of September 30, 2024, the company repurchased a total of 7,855,000 A-shares, accounting for 0.85% of the total share capital, with a total expenditure of RMB 276,508,263.84[12] - The company repurchased 4,763,400 H-shares, with 2,778,800 shares canceled on June 28, 2024, representing 0.21% of the total share capital, and a total expenditure of HKD 116,981,345.00[13] Other Financial Metrics - Financial expenses decreased by 74.63% to RMB -54.93 million, primarily due to reduced interest income and foreign exchange fluctuations[6] - Investment income fell by 48.98% to RMB 25.90 million, mainly due to changes in the profits of associated companies[6] - Research and development expenses were RMB 734,493,897.75, down 25.49% from RMB 985,755,413.94 in the same period last year[17] - Other comprehensive income after tax showed an improvement, with a net amount of RMB -49,894,257.61 compared to RMB -76,284,738.91 in the previous year[18] - The fair value change income was RMB -5.50 million, an improvement of 86.90% compared to RMB -41.99 million in the previous year, mainly due to fluctuations in the market value of securities investments[6]

華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 (Stock code 股份代號: 1513) NOTIFICATION LETTER 通知信函 24 October 2024 Dear Non-Registered Holder(Note), Livzon Pharmaceutical Group Inc.(the "Company") Notification of publication of (1) Circular dated 24 October 2024; (2) Notice of the 2024 Third Extraordinary General Meeting; and (3) Proxy Form (the "Current Corporate Communication") 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* (a joint stock company incorporated in the People's Republic of China with limited liabilit ...

LIVZON PHARMACEUTICAL GROUP INC.* (a joint stock company incorporated in the People's Republic of China with limited liability) （ 於 中 公 司 ） 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 (Stock code 股份代號: 1513) NOTIFICATION LETTER 通知信函 麗 珠 醫 藥 集 團 股 份 有 限 公 司 24 October 2024 Dear Registered Shareholder, Livzon Pharmaceutical Group Inc. (the "Company") Notification of publication of (1) Circular dated 24 October 2024; (2) Notice of the 2024 Third Extraordinary General Meeting; and (3) Proxy Form (the "Current Corporate Commu ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 建議選舉非執行董事 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.*（「本公司」，連同其附屬 公司統稱為「本集團」）謹此宣佈，2024年10月23日，本公司第十一届董事會（「董事會」） 第二十次會議選舉林楠棋先生（「林先生」）為本公司第十一屆董事會非執行董事。林先 生於任期內將有權收取年度董事袍金人民幣玖萬陸仟元正。林先生的酬金已由薪酬與考 核委員會審查，並由董事會參考其於本公司之職責及責任、本公司之薪酬政策及該職位 之市場薪金範圍而釐定。林先生的委任須待本公司股東（「股東」）於本公司二零二四年 第三次臨時股東大會（「臨時股東大會」）以普通決議案審議通過後方可生效。林先生擔 任非執行董事的任期將由股東於臨時股東大會批准其選舉當日開始，並將於第十一屆董事 會任期屆滿時結束。本公司將於其選舉於臨時股東大會獲批准後，與林先生訂立服務協議。 1 林先生的簡歷如下： 林 ...

此乃要件 請即處理 閣下對本通函任何內容如有疑問，應諮詢 閣下的股票經紀或其他註冊證券交易商、銀行 經理、律師、專業會計師或其他專業顧問。 閣下如已出售或轉讓名下所有麗珠醫藥集團股份有限公司的股份，應立即將本通函交予買 方或受讓人或經手出售的銀行、股票經紀或其他代理商，以便轉交買方或受讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產 生或因倚賴該等內容而致的任何損失承擔任何責任。 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1513） (I)向關連附屬公司提供持續擔保 獨立董事委員會及獨立股東之獨立財務顧問 (II)建議募集資金投資項目結項並將節餘募集資金永久補充流動資金 (III)建議選舉非執行董事 及 (IV)臨時股東大會通知 董事會函件載於本通函第6至21頁。獨立董事委員會函件載於本通函第22至23頁，當中載有 其就202 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 特別決議案 1. 審議及批准本公司與控股附屬公司麗珠單抗訂立的2025年-2027年三年持續擔保支持 框架協議，及其項下擬進行的本公司為麗珠單抗提供融資擔保的持續關連交易以及 年度擔保上限。 普通決議案 附註： 1. 根據香港聯合交易所有限公司證券上市規則（「上市規則」），臨時股東大會上所有決議案將以投票方 式進行表決。投票結果將按照上市規則規定刊載於香港交易及結算所有限公司的網站(www. hkexnews.hk)及本公司的網站(www.livzon.com.cn)。 — 1 — 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1513） 二零二四年第三次臨時股東大會通知 茲通告麗珠醫藥集團股份有限公司Livzon Pharmaceutic ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2024-065 丽珠医药集团股份有限公司 关于召开 2024 年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：丽珠医药集团股份有限公司（以下简称"公司"）2024 年 第三次临时股东大会。 2、股东大会的召集人：公司董事会。公司已于 2024 年 10 月 23 日召开了第 十一届董事会第二十次会议，审议并通过了《关于召开 2024 年第三次临时股东 大会的议案》。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件、深交所业务规则和《公司章程》等规定。 4、会议召开的日期、时间： （1）现场会议召开日期、时间：2024 年 11 月 26 日（星期二）下午 2:30； （2）网络投票时间： ①通过互联网投票系统进行网络投票的起止日期和时间：2024 年 11 月 26 日上午 9:15 至 2024 年 11 月 26 日下午 3:00； ②通过交易系统进行网络投票的 ...

Financial Performance - Total revenue for Q3 2024 was ¥2,799,249,537.14, a decrease of 5.59% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2024 was ¥501,763,106.12, an increase of 7.45% year-over-year[3] - Net profit excluding non-recurring gains and losses for Q3 2024 was ¥475,333,392.49, a decrease of 1.36% compared to the same period last year[3] - Basic earnings per share for Q3 2024 was ¥0.54, an increase of 8.00% year-over-year[3] - The company's operating revenue for the first nine months of 2024 was RMB 9,081.60 million, a decrease of 5.94% compared to RMB 9,654.79 million in the same period of 2023[8] - The net profit attributable to shareholders of the parent company for the first nine months of 2024 was RMB 1,672,733,989.63, an increase of 4.44% from RMB 1,601,554,878.96 in the previous year[19] - The company's operating profit for the first nine months of 2024 was RMB 2,315,421,100.65, up 16.49% from RMB 1,987,239,809.53 in the same period of 2023[19] - The total comprehensive income for the first nine months of 2024 was RMB 1,896,000,641.95, an increase from RMB 1,548,036,443.08 in the same period of 2023[20] Assets and Liabilities - Total assets as of the end of Q3 2024 were ¥24,909,308,152.30, a decrease of 0.54% from the end of the previous year[4] - The company's total liabilities increased by 147.35% to RMB 1,631.71 million from RMB 659.68 million, primarily due to the transfer of long-term borrowings due within one year[8] - The total liabilities as of the end of the reporting period were RMB 9,973,518,408.08, a decrease from RMB 10,278,124,131.71 at the beginning of the year[18] - The total current assets decreased from RMB 17,266,174,718.28 at the beginning of the year to RMB 16,613,394,001.59[17] - The non-current assets increased from RMB 7,778,652,409.47 at the beginning of the year to RMB 8,295,914,150.71[17] Shareholder Information - Shareholders' equity attributable to the parent company was ¥14,158,595,462.73, an increase of 0.83% from the end of the previous year[4] - The company reported a total of 926,904,495 shares outstanding as of the latest disclosure date[4] - The total number of ordinary shareholders at the end of the reporting period was 41,320, with the top ten shareholders holding significant stakes, including Hong Kong Central Clearing Limited at 33.11%[10] - The company repurchased a total of 7,855,000 A shares, representing 0.85% of the total share capital, with a total expenditure of RMB 276,508,263.84[13] - The company also repurchased 4,763,400 H shares, with the remaining shares accounting for 0.21% of the total share capital, and a total expenditure of HKD 116,981,345.00[14] Cash Flow - Cash flow from operating activities for the period from January to September 2024 was ¥2,307,915,362.28, an increase of 4.32% year-over-year[3] - The total cash inflow from operating activities for the first nine months of 2024 was CNY 10,217,108,238.70, a decrease of 5.2% compared to CNY 10,775,261,897.57 in the same period of 2023[21] - The net cash flow from operating activities increased to CNY 2,307,915,362.28, up by 4.3% from CNY 2,212,403,355.39 year-on-year[21] - Cash inflow from financing activities increased to CNY 3,166,957,767.39, up 14.3% from CNY 2,770,410,168.70 year-on-year[21] - The ending balance of cash and cash equivalents was CNY 10,723,355,139.50, an increase from CNY 9,995,849,149.30 in the same period last year[21] Financial Ratios and Metrics - The weighted average return on equity for Q3 2024 was 3.56%, an increase of 0.13 percentage points compared to the previous year[3] - The financial expenses decreased by 74.63% to RMB -54.93 million from RMB -216.48 million year-on-year, mainly due to reduced interest income from deposits and foreign exchange losses[8] - The company's financial expenses showed a significant improvement, with a net financial expense of -RMB 54,930,249.12 compared to -RMB 216,475,683.51 in the previous year[19] - Research and development expenses for the first nine months of 2024 amounted to RMB 734,493,897.75, a decrease of 25.49% compared to RMB 985,755,413.94 in the previous year[19] Other Information - Government subsidies recognized in Q3 2024 amounted to ¥32,137,493.67, contributing positively to the financial results[5] - The company did not undergo an audit for the third quarter report[22] - The report indicates that the company has adopted new accounting standards starting from 2024[22]

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2024-063 丽珠医药集团股份有限公司 第十一届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 丽珠医药集团股份有限公司（以下简称"公司"）第十一届董事会第二十次 会议于 2024 年 10 月 23 日以现场和通讯表决相结合的方式召开，会议通知已于 2024 年 10 月 9 日以电子邮件形式发送，现场会议地址为珠海市金湾区创业北路 38 号丽珠工业园总部大楼 9 楼会议室，本次会议应参会董事 10 人，实际参会董 事 10 人，本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定，经与会董事认真审议，作出如下决议： 公司董事会作为召集人，定于 2024 年 11 月 26 日（星期二）采用现场表决 以及网络投票相结合的方式召开公司 2024 年第三次临时股东大会。 表决结果：同意 10 票，反对 0 票，弃权 0 票。 关于召开公司 2024 年第三次临时股东大会的通知已于本公告日披露于《中 国证券报》、《证券时报》、《证券日报 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有 限公司第十一屆董事會第二十次會議決議公告》，僅供參閱。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. * 公司秘書 楊亮 中國，珠海 二零二四年十月二十三日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 及邱慶豐先生 ; 而本公司 的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗婕女士。 * 僅供識別 1 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2024-063 丽珠医药集团股份有限公司 第十 ...